SCHEMBL1703153

SCHEMBL1703153

N#Cc1c(-c2ccc(NC(=O)Nc3ccc(F)c(Cl)c3)cc2)ccnc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.57
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
LMNA P02545 3/20 0.56
MAPT P10636 3/20 0.56
HTT P42858 4/20 0.52
TP53 P04637 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
SLC2A1 P11166 1/20 0.51
KIT P10721 2/20 0.48
FLT3 P36888 2/20 0.48
PIK3R1 P27986 1/20 0.47
PIK3CA P42336 1/20 0.47
CA2 P00918 1/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
ABL1 P00519 1/20 0.45
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703172 0.89 KDR (0.56) KDRMEN1KMT2ALMNAMAPT
SCHEMBL1703125 0.88 KDR (0.60) KDRKITFLT3ABL1LCK
SCHEMBL1703220 0.87 KDR (0.53) KDRRAB9ASMN1; SMN2KITFLT3
SCHEMBL3443154 0.86 CYP3A4 (0.58) KDRMEN1KMT2ALMNATP53
SCHEMBL3442461 0.86 CYP3A4 (0.60) KDRMEN1KMT2ALMNAMAPT
SCHEMBL1702911 0.85 KDR (0.60) KDRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3442309 0.83 MEN1 (0.57) KDRMEN1KMT2ALMNAMAPT
SCHEMBL1703031 0.83 KDR (0.60) KDRKITFLT3CA2ABL1
SCHEMBL1703490 0.82 KIT (0.57) KDRMEN1KMT2AKITFLT3
SCHEMBL1703595 0.82 CYP3A4 (0.58) KDRKMT2ASMN1; SMN2KITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885MEN1 2491/4885KMT2A 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.